- Home
- XFOR vs PACB Comparison
XFOR vs PACB Comparison
Compare XFOR & PACB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | XFOR | PACB |
|---|---|---|
| Founded | 2014 | 2000 |
| Country | United States | United States |
| Employees | 143 | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Laboratory Analytical Instruments |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 407.5M | 419.8M |
| IPO Year | N/A | 2010 |
Fundamental Metrics
Financial Performance| Metric | XFOR | PACB |
|---|---|---|
| Price | $4.41 | $1.35 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 4 |
| Target Price | ★ $25.20 | $2.13 |
| AVG Volume (30 Days) | 495.0K | ★ 5.5M |
| Earning Date | 03-17-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $93,468,000.00 |
| Revenue This Year | N/A | $11.22 |
| Revenue Next Year | $80.31 | $12.41 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 3.04 |
| 52 Week Low | $0.17 | $0.85 |
| 52 Week High | $6.63 | $2.73 |
Technical Indicators
Market Signals| Indicator | XFOR | PACB |
|---|---|---|
| Relative Strength Index (RSI) | 58.40 | 43.13 |
| Support Level | $3.01 | $1.19 |
| Resistance Level | $4.83 | $1.40 |
| Average True Range (ATR) | 0.36 | 0.08 |
| MACD | 0.01 | 0.02 |
| Stochastic Oscillator | 88.27 | 56.82 |
Price Performance
Historical ComparisonAbout XFOR X4 Pharmaceuticals Inc.
X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare diseases of the immune system. The Company's lead clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.
About PACB Pacific Biosciences of California Inc.
Pacific Biosciences of California Inc is a biotechnology company focused on designing, developing, and manufacturing sequencing solutions that enable scientists and clinical researchers to improve their understanding of the genome and ultimately, resolve genetically complex problems. It operates in, one reportable segment: the development, manufacturing, and marketing of an integrated platform for genetic analysis. The majority of the company's revenue is derived from Americas, followed by Europe Middle East, and Africa and Asia-Pacific.